Raiffeisen Bank International AG Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Raiffeisen Bank International AG increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.7% during the 2nd quarter, Holdings Channel reports. The fund owned 13,510 shares of the biopharmaceutical company’s stock after purchasing an additional 3,097 shares during the quarter. Raiffeisen Bank International AG’s holdings in Alnylam Pharmaceuticals were worth $3,965,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. denkapparat Operations GmbH increased its holdings in Alnylam Pharmaceuticals by 151.4% during the 2nd quarter. denkapparat Operations GmbH now owns 2,594 shares of the biopharmaceutical company’s stock worth $781,000 after purchasing an additional 1,562 shares during the period. Concurrent Investment Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 695.9% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 7,521 shares of the biopharmaceutical company’s stock valued at $2,264,000 after buying an additional 6,576 shares during the period. NEOS Investment Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 13.6% in the 2nd quarter. NEOS Investment Management LLC now owns 78,274 shares of the biopharmaceutical company’s stock valued at $23,563,000 after buying an additional 9,401 shares during the period. Nykredit A S acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $15,415,000. Finally, B. Metzler seel. Sohn & Co. AG grew its position in shares of Alnylam Pharmaceuticals by 25.0% during the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,591 shares of the biopharmaceutical company’s stock worth $3,188,000 after buying an additional 2,116 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $266.11 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The firm has a market capitalization of $35.61 billion, a PE ratio of 49.46 and a beta of 0.31. The stock’s 50-day simple moving average is $259.25 and its 200-day simple moving average is $291.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm’s revenue was up 66.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.51) earnings per share. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several analyst reports. Oppenheimer reduced their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Wells Fargo & Company lowered their price target on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. JPMorgan Chase & Co. dropped their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Sanford C. Bernstein restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday. Finally, Stifel Nicolaus reduced their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $386.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.